GOLDEN, Colo. — August 16, 2022 — PharmaJet® , a company that has developed and commercialized a needle-free platform to more effectively administer drugs and biologics announced that its partner, University of Adelaide, has started a human trial of a DNA-based COVID-19 vaccine booster using the PharmaJet Tropis® Needle-free Injection
Read more
GOLDEN, Colo. — August 2, 2022 — PharmaJet® , a biotech company that, with their innovative needle-free technology has developed a more effective way of administering drugs and biologics to accelerate research, commercialization and public health outcomes, announced that its partner, Scancell, will include needle-free delivery of their Phase 2
Read more
PharmaJet presents latest research showing Benefits of Needle-free at mRNA-Based Therapeutics Summit
GOLDEN, Colo. — July 19, 2022 — PharmaJet® , a company who has developed and commercialized a needle-free platform to more effectively administer drugs and biologics, today announced that they will present their latest research results at the mRNA-Based Therapeutics Summit on July 27, 2022. The presentation, entitled Advances in
Read more
GOLDEN, Colo. — July 5, 2022—PharmaJet®, a biotech company that, with their innovative needle-free technology has developed a more effective way of administering drugs and biologics to accelerate research, commercialization and public health outcomes, today announced that their latest research results were presented at the BIO International Convention in June.
Read more
GOLDEN, Colo. — June 21, 2022 — PharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, announced that its partner, Nykode Therapeutics announced positive interim results from its phase 2 trial of their novel candidate, VB10.16, in
Read more
GOLDEN, Colo. — June 7, 2022 — PharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, today announced that the phase 3 clinical study sponsored by their partner, Zydus Lifesciences, has been published in The Lancet. The
Read more
GOLDEN, Colo. — May 24, 2022 — PharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, announced that its partner, the Institute for Molecular Medicine (IMM) was awarded a $12 Million grant from the National Institute on
Read more
GOLDEN, Colo. — May 10, 2022 — PharmaJet ®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, today announced that Darin Zehrung has joined the executive leadership team as Chief Business Development Officer. Mr. Zehrung is a
Read more
GOLDEN, Colo. — April 27, 2022 — PharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, today announced that their latest research results were presented at the World Vaccine Congress on April 20. The presentation, entitled Benefits of
Read more
GOLDEN, Colo. — April 13, 2022 — PharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, today announced the launch of their new website aimed at expanding partner support with on-line tools for more rapid and efficient
Read more
GOLDEN, Colo. — March 29, 2022 — PharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, announced the release of a video highlighting the recent implementation of a polio vaccination campaign in Somalia.
Read more
GOLDEN, Colo. — March 15, 2022 — PharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, announced that its partner Immunomic Therapeutics will be starting a phase 1 clinical study of their plasmid DNA vaccine ITI-3000 in
Read more